Daniela Michel

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i> -Mutant Melanoma

Jean‐Pierre Delord, Caroline Robert, Marta Nyakas et al. · Clinical Cancer Research · 2017 · 184 citations · Full text

Pathogen-Mediated Inhibition of Anorexia Promotes Host Survival and Transmission

Sheila Rao, Alexandria M. Palaferri Schieber, Carolyn O’Connor et al. · Cell · 2017 · 170 citations · Full text

High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea

Ivo Müeller, S. Widmer, Daniela Michel et al. · Malaria Journal · 2009 · 106 citations · Full text

Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study

Carlos Gomez‐Roca, Jean‐Pierre Delord, Caroline Robert et al. · Annals of Oncology · 2014 · 47 citations

Oncology, Oral Braf Inhibitor, Gastrointestinal Oncology +10

Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.

Reinhard Dummer, Caroline Robert, Marta Nyakas et al. · Journal of Clinical Oncology · 2013 · 45 citations

Immunology, Pathology, Immunotherapeutics +18